KIDS
OrthoPediatrics Corp.17.91
-0.08-0.45%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Eyes subspecialty expansion beyond ortho.
Q&A largely reaffirmed prepared remarks on OrthoPediatrics' robust pipeline and guidance, but management elaborated on leveraging its pediatric hospital footprint to expand into less capital-intensive subspecialties like ENT via IotaMotion and cardiovascular, hinting at M&A or partnerships for shareholder value. Scoliosis grew strongly amid competition, driven by VerteGlide share gains in new accounts and EU MDR approvals enabling full portfolio conversions. New products command pricing premiums with attractive margins; R&D stays efficient despite spend swings. Playbook debuts as first-of-kind digital workflow tool for peds ortho. Subspecialty traction matters for the thesis.
Key Stats
Market Cap
449.13MP/E (TTM)
-Basic EPS (TTM)
-1.96Dividend Yield
0%Recent Filings
10-K
FY2025 results
OrthoPediatrics drove FY2025 revenue to $236.3M, up 15% y/y from $204.7M, with trauma & deformity at $166.3M (+15%) and scoliosis surging 20% to $66.0M on stronger RESPONSE and 7D sales—yet Q4 momentum stayed steady amid acquisitions like Boston O&P clinics. Gross margins held firm at 73%, but operating loss widened to $39.2M from set deployments and $4.6M intangible impairments. Cash burn eased to $4.9M from operations; $100M Braidwell debt funded growth, leaving $62.9M liquidity. No annual guidance disclosed. Clinic reimbursement cuts could crimp quarterly momentum.
8-K
Record revenue, cash flow inflection
OrthoPediatrics posted record 2025 revenue of $236.3 million, up 15% from 2024, with Q4 at $61.6 million, up 17%. Adjusted EBITDA hit $14.8 million for the year, nearly doubling to $4.8 million in Q4. Cash flow turned positive with $9.8 million free cash flow in Q4. Guides 2026 revenue to $262-266 million, $25 million adjusted EBITDA, breakeven cash flow.
8-K
OrthoPediatrics 2025 results, 2026 guidance
OrthoPediatrics disclosed its February 2026 investor presentation under Item 7.01, highlighting 2025 revenue of $236.3M, up 15% from $204.7M, driven by trauma & deformity ($166.3M) and scoliosis ($66.0M). Adjusted EBITDA hit $14.8M while narrowing GAAP net loss to $39.6M. Issued FY2026 revenue guidance of $262M-$266M. Cash reserves stand at $62.9M.
8-K
Record $236M revenue, 2026 guidance
OrthoPediatrics posted record preliminary unaudited 2025 revenue of $236.1 million, up 15% from $204.7 million in 2024, with Q4 at $61.3 million, up 16%. Domestic revenue hit $186.2 million (16% growth); international $49.9 million (15%). Free cash flow usage dropped over 50% from 2024. Guides 2026 revenue to $262-266 million, with $25 million Adjusted EBITDA. Numbers await audit.
8-K
2026 investor presentation filed
OrthoPediatrics furnished its January 2026 investor presentation under Regulation FD, highlighting 2025 unaudited revenue of $236.1M, up 15% from $204.7M in 2024, driven by 16% U.S. growth. Trauma & deformity dominates at 71% of sales. Guides 2026 revenue to $262-266M with ~$25M Adjusted EBITDA. Sales accelerate via acquisitions, yet non-GAAP metrics lack full reconciliation.
IPO
Employees
Sector
Industry
BSX
Boston Scientific Corporation
92.95+0.76
CNMD
CONMED Corporation
39.20-1.12
DYNT
Dynatronics Corp.
0.04+0.00
ENOV
Enovis Corporation
26.07-0.47
EW
Edwards Lifesciences Corporatio
85.32+1.94
OFIX
Orthofix Medical Inc.
15.55-0.16
SNN
Smith & Nephew SNATS, Inc.
32.31+0.08
SYK
Stryker Corporation
351.69-3.62
TMCI
Treace Medical Concepts, Inc.
2.70-0.07
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52